Stated plainly: orforglipron · 5 mg/mL · sixteen weeks.
This is asserted often enough that I assumed it was established, and then I went looking for the source.
I have searched the primary literature and found one paper that is adjacent but not on point.
Can anyone point me at a primary source, or confirm that there is not one?
sixteen weeks is 112 days and, on a weekly schedule, 16 stopper punctures out of one vial at 5 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 112 days is 4 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 5 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 16 withdrawals do add is 16 opportunities to introduce air, 16 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.
This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
| State | Condition | Usable window | Basis |
|---|---|---|---|
| Lyophilised solid | −20 °C, sealed, dry | 24–36 months | Supplier guidance |
| Lyophilised solid | 2–8 °C, sealed | 12–24 months | Supplier guidance |
| Lyophilised solid | 25 °C, sealed | 4–8 weeks | Extrapolated (Arrhenius) |
| Lyophilised solid | 40 °C, sealed | 1–2 weeks | Extrapolated |
| Solution, preserved | 2–8 °C | 28 days | USP microbiological convention |
| Solution, preserved | 25 °C | 3–7 days | Extrapolated |
| Solution, unpreserved | 2–8 °C | 24 hours | USP microbiological convention |
Windows for the solid state are chemical; windows for solution are microbiological and usually shorter than the chemical limit.
The underlying point is that deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
More usefully, freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
At dilute concentrations, suspect adsorption before you suspect chemistry.
Start with the sequence, because which pathways are available depends on which residues are present.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Sequence decides which pathways are even available. Check the residues.
Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.
Cold, dry, dark, still. Those four words cover most of the mitigation.
edited 13 Nov 2024 by halvard_ness — corrected a unit error in the worked example
The part that matters: aggregation is a physical process and is the one most often caused by handling rather than by time.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Sequence determines which pathways apply, so general statements are general.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
edited 28 Nov 2024 by esben_lykke — expanded the table to cover the lower concentration
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.